100
Participants
Start Date
March 17, 2021
Primary Completion Date
August 31, 2021
Study Completion Date
October 8, 2021
Lifitegrast 5% Ophthalmic Solution
Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
Bowden Eye & Associates, Jacksonville
Cleveland Eye Clinic, Brecksville
Harvard Eye Associates, Laguna Hills
Research Insight LLC
INDUSTRY